Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. - Wikidata - wikimedia - TriplyDB

Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.

Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.

http://www.wikidata.org/entity/Q38093852

about

Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.The challenges of LC-MS/MS analysis of opiates and opioids in urine.Buprenorphine--the unique opioid adjuvant in regional anesthesia.Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response.Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids.Management of opioid use disorders: a national clinical practice guideline.A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study.Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.

P2860

Q33833207-3E476259-4C9F-476A-9608-D80C88D99B36 Q34952233-4491356E-65ED-4F40-AFB0-7475E47639BF Q37429615-3616384E-C90A-4405-9E0E-CFE923151FFA Q38164427-F8086563-6004-488E-89A7-9279A9E3C855 Q38694075-5D428510-33B9-4CE4-9777-831CE8D0DCF8 Q38870014-4CD1ED50-253F-4481-AA2F-1EDD4B2AFC9F Q42097867-5A80FDD8-C153-4EDE-8CB9-FF69B3D1EF90 Q52316126-2B7AE95D-898A-4A28-B7B5-9BC17CE1ADF3 Q53531239-B8948CC7-CD9C-4FC8-9818-9B319AC49E8E Q53544619-4047F7F5-0E0E-49FE-A072-E680E3EF890F

P2860

Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.

http://www.wikidata.org/entity/Q38093852

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Metabolic and toxicological co ...... : methadone and buprenorphine.

@en

type

label

Metabolic and toxicological co ...... : methadone and buprenorphine.

@en

prefLabel

Metabolic and toxicological co ...... : methadone and buprenorphine.

@en

P1433

Q38093852-8DA6A7DF-77CC-4D66-9C54-B491884001AD

P1476

Q38093852-1DBDB86A-B23D-4C8B-9324-59E49EF52108

P2093

Q38093852-C155FC93-C55E-42EF-9417-2740AD5BD195

P2860

Q38093852-01968DC8-141F-4631-8F24-8E0E671B8C66

Q38093852-0437F67F-D42A-4365-9273-66F73166FFFE

Q38093852-049F1C0F-6654-42D8-AE53-2484757216BF

Q38093852-04BFF563-76B7-4C7C-860C-77457D753FA9

Q38093852-090446E4-4D70-4D9A-B897-844DE5757FC1

Q38093852-090F42A7-2E57-4BF2-87EE-05343DC7B6AC

Q38093852-0E449051-9003-4C20-9A99-D142489A3575

Q38093852-0E837337-DC82-4CF8-99FB-73ABE75BE485

Q38093852-0FD3E0EC-4BAC-4DCE-A4BD-787932E0A09D

Q38093852-143A7AE0-6822-4484-8CA1-51B71DFCDA26

P304

Q38093852-A985B73E-2087-462D-A58D-5CB991E642D2

P31

Q38093852-76B2A276-FBFD-4DF4-B3BD-D35FBD2E8156

P356

Q38093852-676335CA-2F57-4878-9BDC-F52D7C9A759B

P407

Q38093852-4537D787-6918-4F04-BC76-7056F454B460

P433

Q38093852-AA238106-9D2E-411E-AD3F-9C1A84FBE67D

P478

Q38093852-578A3E0A-D78C-4383-AD50-0820454D06D6

P577

Q38093852-6331F4A6-D386-4747-910C-0633E973D90C

P698

Q38093852-75015618-E0FB-4C1F-9815-2A55ECF3BD80

P921

Q38093852-7ac45b35-0a87-45ab-ae75-42287c997c36

P356

17425255.2013.783567

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Metabolic and toxicological co ...... : methadone and buprenorphine.

@en

P2093

David E Moody

http://www.w3.org/2001/XMLSchema#string

P2860

Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4

P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception

Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes

μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology

Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes

OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS).

2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report.

P304

675-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.783567

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23537174

http://www.w3.org/2001/XMLSchema#string

P921